Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

STRIDES PHARMA SCIENCE LIMITED Capital/Financing Update 2019

Jul 1, 2019

62616_rns_2019-07-01_579bb62c-bc40-421e-b2f5-6354bbfdebd6.pdf

Capital/Financing Update

Open in viewer

Opens in your device viewer

July 1, 2019

BSE Limited

Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 Scrip code: 532531

The National Stock Exchange of India Limited

Exchange Plaza, Bandra-Kurla Complex Bandra (E) Mumbai - 400 051 Scrip code: STAR

Dear Sirs,

Sub: Update on “Strides to exit its investment in Arrow for AUD 394 Million”

Further to our earlier communication relating to “Strides to exit its investment in Arrow for AUD 394 Million”, we wish to inform you that all requisite approvals are received and Strides Pharma Global Pte Limited (SPG), a step-down subsidiary of the Company in Singapore, has signed the definitive agreements for the transaction.

The Company expects the transaction to close on or around July 10, 2019. SPG will receive AUD 300 Million immediately at closing and balance AUD 94 Million will be received as deferred consideration backed by a secured interest-bearing instrument.

You are requested to take the same on record.

For Strides Pharma Science Limited

==> picture [114 x 47] intentionally omitted <==

Manjula Ramamurthy Company Secretary

==> picture [85 x 82] intentionally omitted <==

Strides Pharma Science Limited

(Formerly Strides Shasun Limited) CIN: L24230MH1990PLC057062 Corp Off : Strides House, Bilekahalli, Bannerghatta Road, Bangalore - 560 076, India Tel: +91 80 6784 0000 Fax: +91 80 6784 0700 Regd Off : 201, Devavrata, Sector 17, Vashi, Navi Mumbai – 400 703, India Tel: +91 22 2789 2924 / 3199 Fax: +91 22 2789 2942 [email protected]; www.strides.com